Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FZ006
- Development stage
- Preclinical
- Lead developer
- FZata
- Modality
- Gene Silencing → Gene Therapies, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Editing → Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Addition/Replacement → Gene Therapies
- Administration
- Oral
01
Overview
FZ006 is an oral capsule drug candidate developed by Fzata. It consists of genetically engineered lyophilized yeast that expresses a proprietary tumor necrosis factor alpha (TNF-α) blocker. The drug acts as a gastrointestinal microbiome modulator and TNF-α inhibitor, aiming to provide anti-inflammatory effects within the gut. Its primary indication is for chronic visceral pain associated with inflammatory bowel syndrome (IBS), and it is also being investigated for ulcerative colitis and other inflammatory bowel diseases. The product leverages probiotic yeast as a delivery vehicle for the therapeutic protein, representing an innovative approach combining gene therapy and live biotherapeutic modalities. As of August 2024, FZ006 remains in preclinical development[1][2][3][4].
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on FZ006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FZ006.